Global Perspectives in Breast Cancer

Expert perspectives and strategic insights on the latest therapeutic developments in breast cancer

April 22 and 23, 2022

Faculty Chair

Joyce O’Shaughnessy, MD

Texas Oncology, Dallas, TX, USA

Faculty Members

Hope Rugo, MD, FASCO
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Mark Pegram, MD
Stanford Women’s Cancer Center, Palo Alto, CA, USA

William Gradishar, MD
Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Jame Abraham, MD, FACP
Cleveland Clinic, Cleveland, OH, USA

Adam Brufsky, MD, PhD, FACP
University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

Komal L. Jhaveri, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Peter Kaufman, MD
University of Vermont, Burlington, VT, USA

William Sikov, MD
Women & Infants Hospital of Rhode Island, Providence, RI, USA

Harold Burstein, MD, PhD
Dana-Farber Cancer Institute, Boston, MA, USA

Sample Report

Start discovering the insights

View Report

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

The meeting report will be based on the following topics

  • Evolving Paradigms in HER2+ MBC
  • Individualizing Therapy for HER2+ Early Breast Cancer
  • Current and Investigational Approaches in Metastatic Triple-Negative Breast Cancer
  • Standard and Emerging Strategies for High-Risk Early Stage Triple-Negative Breast Cancer
  • Novel Targets in Breast Cancer
  • Evolving Treatments and New Developments in HR+ Metastatic Breast Cancer
  • Evolving Paradigms in HR+ Early Breast Cancer

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.